(Q44468701)

3 December 2017

title

Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae (English)

1 reference

3 December 2017

main subject

Mycoplasma pneumoniae

object named as

Mycoplasma pneumoniae

1 reference

Ken B Waites

1

1 reference

3 December 2017

Donna M Crabb

series ordinal

2

1 reference

3 December 2017

Lynn B Duffy

series ordinal

3

1 reference

3 December 2017

publication date

1 June 2003

1 reference

International Journal of Antimicrobial Agents

3 December 2017

published in

1 reference

3 December 2017

volume

21

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

574-577

1 reference

Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900060-8

7 January 2021

10.1016/S0924-8579(03)00060-8

Identifiers

DOI

1 reference

3 December 2017

1 reference